Elicio Therapeutics Statistics
Total Valuation
ELTX has a market cap or net worth of $83.20 million. The enterprise value is $91.62 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ELTX has 15.94 million shares outstanding. The number of shares has increased by 141.35% in one year.
| Current Share Class | 15.94M |
| Shares Outstanding | 15.94M |
| Shares Change (YoY) | +141.35% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 35.58% |
| Owned by Institutions (%) | 13.12% |
| Float | 10.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | -7.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80
| Current Ratio | 1.80 |
| Quick Ratio | 1.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -98.87 |
Financial Efficiency
Return on equity (ROE) is -170,157.38% and return on invested capital (ROIC) is -170.31%.
| Return on Equity (ROE) | -170,157.38% |
| Return on Assets (ROA) | -101.64% |
| Return on Invested Capital (ROIC) | -170.31% |
| Return on Capital Employed (ROCE) | -270.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.62M |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.41% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -46.41% |
| 50-Day Moving Average | 7.08 |
| 200-Day Moving Average | 5.66 |
| Relative Strength Index (RSI) | 39.03 |
| Average Volume (20 Days) | 44,102 |
Short Selling Information
The latest short interest is 156,689, so 0.98% of the outstanding shares have been sold short.
| Short Interest | 156,689 |
| Short Previous Month | 170,043 |
| Short % of Shares Out | 0.98% |
| Short % of Float | 1.53% |
| Short Ratio (days to cover) | 4.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -44.99M |
| Pretax Income | -38.99M |
| Net Income | -51.90M |
| EBITDA | -44.67M |
| EBIT | -44.99M |
| Earnings Per Share (EPS) | -$4.25 |
Full Income StatementBalance Sheet
The company has $17.62 million in cash and $26.04 million in debt, giving a net cash position of -$8.42 million or -$0.53 per share.
| Cash & Cash Equivalents | 17.62M |
| Total Debt | 26.04M |
| Net Cash | -8.42M |
| Net Cash Per Share | -$0.53 |
| Equity (Book Value) | -11.31M |
| Book Value Per Share | -1.03 |
| Working Capital | 9.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$37.07 million and capital expenditures -$87,000, giving a free cash flow of -$37.16 million.
| Operating Cash Flow | -37.07M |
| Capital Expenditures | -87,000 |
| Free Cash Flow | -37.16M |
| FCF Per Share | -$2.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |